Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Masonic Cancer Center, University of Minnesota
With
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have solid organ tumors refractory to currently available treatments.
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Have a life expectancy of 4 months
Have normal organ and bone marrow function
You may not be if
Have had biologic, hormonal, anti-neoplastic chemotherapy, or radiation therapy within 4 weeks prior to the 1st dose of the study drug or those who have not recovered from adverse events from agents administered more than 4 weeks earlier.
Use of investigational agent in the 4 weeks prior to 1st dose of the study drug
Use of immunosuppressive therapy in the 4 weeks prior to the 1st dose
Have a history of, or clinical evidence of, myocardial ischemia, congestive heart failure, or myocardial arrhythmias requiring treatment within the past 6 months
Have uncontrolled intercurrent or chronic illness, but not limited to, ongoing or active infection such as hepatitis B or C, immune dysfunction such as autoimmune disease, endocrine dysfunction such as hypo- or hyperthyroidism, psychiatric illness such as depression or suicidal tendency or social situations that would limit compliance with study requirements
Have a history of disease requiring ongoing steroid treatment
Have a history of seizure disorders uncontrolled on medication
Have a history of clinically significant coagulation or bleeding disorders or abnormalities
Are HIV positive. HIV positive subjects are excluded from the study because of possible interactions with the immunomodulatory effects of 852A and because of potential pharmacokinetic interactions associated with combination retroviral therapy.
Are pregnant or lactating
Clareo Health | Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors
